<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898401</url>
  </required_header>
  <id_info>
    <org_study_id>2455</org_study_id>
    <nct_id>NCT03898401</nct_id>
  </id_info>
  <brief_title>Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis</brief_title>
  <official_title>Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands: Ministry of Health, Welfare and Sports</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      30 postmenopausal females with senile vaginitis will be enrolled with score of &lt;15 on the
      Gloria Bachman Vaginal Health Index (VHI) intramucosal injections of PRP will be adminstered
      and perform clinical evaluations at 0, 1, 3, and 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 postmenopausal females with senile vaginitis will be enrolled with score of &lt;15 on the
      Gloria Bachman Vaginal Health Index (VHI) intramucosal injections of PRP will be adminstered
      and perform clinical evaluations at 0, 1, 3, and 6 months.

      The patients will be seen in Ain shams university gynecological clinic and will not be paid
      either to receive the procedure or to complete the survey. All patients were fully informed
      of the innovative therapeutic and experimental nature of the localized PRP injection and
      consented to the procedure.

      The materials and equipment included the following:

        1. 5 cc syringes.

        2. 27 gauge needles.

        3. Centrifuge with proprietary collection system.

        4. Calcium chloride 10% (for activation of PRP).

        5. and a topical anesthetic cream compounded with a base that prevents irritation and
           promotes absorption through the vaginal mucosa. Active ingredients will be as follows:
           bupivicaine, lidocaine, and tetracaine with percent concentrations of 20/8/8
           respectively.

      First, a topical anesthetic cream will be applied to the posterior vaginal wall. Delaying the
      PRP injection for 20 minutes after anesthetic application achieved complete or near complete
      analgesia for the procedure. Peripheral blood will be drawn from the arm and centrifuged to
      yield 5 cc of PRP. The RegenÂ® system concentrates 5ml of PRP from 10 ml of whole blood using
      a gel separator.

      Study Interventions:

      After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to
      activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth
      factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin
      matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than
      10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal
      wall and perform clinical evaluations at 0, 1, 3, and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of vaginal mucosa using vaginal health index score</measure>
    <time_frame>6 months</time_frame>
    <description>Elasticity,fluid volume,integrity,pH,moisture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Distress (FSD) scale</measure>
    <time_frame>6 months</time_frame>
    <description>How often did you feel distreesed about your sexual life ?</description>
  </secondary_outcome>
  <number_of_arms>30</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Senile Vaginitis</condition>
  <arm_group>
    <arm_group_label>1 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>17 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>19 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>21 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>23 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>26 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>27PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>28 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>29 PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 PRp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion criteria:
I. Postmenopausal for at least 3 years. II. Vaginal health index &lt;15. III. Any parity.
Exclusion criteria:
I. Women with vaginal infection. II. Women taking estrogen therapy for senile vaginitis. III. Any patient with medical disorder especially diabetes mellitus. IV. Previous vaginal surgery as fistula repair or classical repair. V. Vaginal prolapse VI. Any patient taking chemo or radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Platelet rich plasma</intervention_name>
    <description>After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.</description>
    <arm_group_label>1 PRP</arm_group_label>
    <arm_group_label>10 PRP</arm_group_label>
    <arm_group_label>11 PRP</arm_group_label>
    <arm_group_label>12 PRP</arm_group_label>
    <arm_group_label>13 PRP</arm_group_label>
    <arm_group_label>14 PRP</arm_group_label>
    <arm_group_label>15 PRP</arm_group_label>
    <arm_group_label>16 PRP</arm_group_label>
    <arm_group_label>17 PRP</arm_group_label>
    <arm_group_label>18 PRP</arm_group_label>
    <arm_group_label>19 PRP</arm_group_label>
    <arm_group_label>2 PRP</arm_group_label>
    <arm_group_label>20 PRP</arm_group_label>
    <arm_group_label>21 PRP</arm_group_label>
    <arm_group_label>22 PRP</arm_group_label>
    <arm_group_label>23 PRP</arm_group_label>
    <arm_group_label>24 PRP</arm_group_label>
    <arm_group_label>25 PRP</arm_group_label>
    <arm_group_label>26 PRP</arm_group_label>
    <arm_group_label>27PRP</arm_group_label>
    <arm_group_label>28 PRP</arm_group_label>
    <arm_group_label>29 PRP</arm_group_label>
    <arm_group_label>3 PRP</arm_group_label>
    <arm_group_label>30 PRp</arm_group_label>
    <arm_group_label>4 PRP</arm_group_label>
    <arm_group_label>5 PRP</arm_group_label>
    <arm_group_label>6 PRP</arm_group_label>
    <arm_group_label>7 PRP</arm_group_label>
    <arm_group_label>8 PRP</arm_group_label>
    <arm_group_label>9 PRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal for at least 3 years.

          -  Vaginal health index &lt;15.

          -  Any parity.

        Exclusion Criteria:

          -  Women with vaginal infection.

          -  Women taking estrogen therapy for senile vaginitis.

          -  Any patient with medical disorder especially diabetes mellitus.

          -  Previous vaginal surgery as fistula repair or classical repair.

          -  Vaginal prolapse

          -  Any patient taking chemo or radiotherapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasha Medhat, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rasha Medhat, Professor</last_name>
    <phone>01224448449</phone>
    <email>rashamedhat30@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain shams University</name>
      <address>
        <city>Cairo</city>
        <state>Elabbasia</state>
        <zip>13211</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasha Abdulhady</last_name>
      <phone>01224448449</phone>
      <email>rashamedhat30@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rasha Abdulhady</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain shams university hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasha M Abdul-hady, Lecturer</last_name>
      <phone>+20122 444 8449</phone>
      <email>Rashamedhat30@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>rasha medhat abdul-hady</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Atrophic Vaginitis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

